We analysed the relevance of SLC2A3 expression to the overall survival of AML patients in 338 cases from The Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. This evidence concerns the gene SLC2A3 and acute myeloid leukemia.